Literature DB >> 34785041

Low physical activity is associated with two hypokinetic motor abnormalities in psychosis.

Sebastian Walther1, Irena Vladimirova2, Danai Alexaki2, Lea Schäppi2, Kathrine S F Damme3, Vijay A Mittal4, Stewart A Shankman4, Katharina Stegmayer2.   

Abstract

Individuals with schizophrenia engage in more sedentary behavior than healthy controls, which is thought to contribute to multiple health adversities. Age, medication side effects and environment are critical determinants of physical activity in psychosis. While motor abnormalities are frequently observed in psychosis, their association with low physical activity has received little interest. Here, we aimed to explore the association of actigraphy as an objective measure of physical activity with clinician assessed hypokinetic movement disorders such as parkinsonism and catatonia. Furthermore, we studied whether patients with current catatonia would differ on motor rating scales and actigraphy from patients without catatonia. In 52 patients with schizophrenia spectrum disorders, we cross-sectionally assessed physical activity using wrist actigraphy and ratings of catatonia, parkinsonism, and negative syndrome. The sample was enriched with subjects with severe psychomotor slowing. Lower activity levels correlated with increased age and severity of catatonia and parkinsonism. The 22 patients with catatonia had lower activity as well as higher scores on parkinsonism, involuntary movements, and negative symptoms compared to the 30 patients without catatonia. Collectively, these results suggest that various hypokinetic motor abnormalities are linked to lower physical activity. Therefore, future research should determine the direction of the associations between hypokinetic motor abnormalities and physical activity using longitudinal assessments and interventional trials.
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Actigraphy; Cardiometabolic health; Catatonia; Schizophrenia

Mesh:

Year:  2021        PMID: 34785041      PMCID: PMC8792361          DOI: 10.1016/j.jpsychires.2021.11.014

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  53 in total

1.  Moving forward: distinct sensorimotor abnormalities predict clinical outcome after 6 months in patients with schizophrenia.

Authors:  Fabio Sambataro; Stefan Fritze; Mahmoud Rashidi; Cristina E Topor; Katharina M Kubera; Robert C Wolf; Dusan Hirjak
Journal:  Eur Neuropsychopharmacol       Date:  2020-06-07       Impact factor: 4.600

2.  Objectively measured motor activity in schizophrenia challenges the validity of expert ratings.

Authors:  Sebastian Walther; Philipp Koschorke; Helge Horn; Werner Strik
Journal:  Psychiatry Res       Date:  2009-09-02       Impact factor: 3.222

3.  Higher motor activity in schizophrenia patients treated with olanzapine versus risperidone.

Authors:  Sebastian Walther; Helge Horn; Nadja Razavi; Philipp Koschorke; Alexander Wopfner; Thomas J Müller; Werner Strik
Journal:  J Clin Psychopharmacol       Date:  2010-04       Impact factor: 3.153

Review 4.  Motor Abnormalities: From Neurodevelopmental to Neurodegenerative Through "Functional" (Neuro)Psychiatric Disorders.

Authors:  Victor Peralta; Manuel J Cuesta
Journal:  Schizophr Bull       Date:  2017-09-01       Impact factor: 9.306

5.  Psychomotor Slowing in Schizophrenia: Implications for Endophenotype and Biomarker Development.

Authors:  K Juston Osborne; Sebastian Walther; Stewart A Shankman; Vijay A Mittal
Journal:  Biomark Neuropsychiatry       Date:  2020-05-12

6.  The diagnostic criteria and structure of catatonia.

Authors:  Jo Ellen Wilson; Kathy Niu; Stephen E Nicolson; Stephen Z Levine; Stephan Heckers
Journal:  Schizophr Res       Date:  2015-01-13       Impact factor: 4.939

7.  Less structured movement patterns predict severity of positive syndrome, excitement, and disorganization.

Authors:  Sebastian Walther; Fabian Ramseyer; Helge Horn; Werner Strik; Wolfgang Tschacher
Journal:  Schizophr Bull       Date:  2013-03-15       Impact factor: 9.306

8.  Quantitative psychomotor dysfunction in schizophrenia: a loss of drive, impaired movement execution or both?

Authors:  Lise Docx; Bernard Sabbe; Pieter Provinciael; Niel Merckx; Manuel Morrens
Journal:  Neuropsychobiology       Date:  2013-11-13       Impact factor: 2.328

Review 9.  All roads lead to the motor cortex: psychomotor mechanisms and their biochemical modulation in psychiatric disorders.

Authors:  Paola Magioncalda; Matteo Martino; Georg Northoff; Dusan Hirjak; Robert C Wolf
Journal:  Mol Psychiatry       Date:  2020-06-17       Impact factor: 15.992

View more
  5 in total

1.  Dynamic Interrogation of Stochastic Transcriptome Trajectories Using Disease Associated Genes Reveals Distinct Origins of Neurological and Psychiatric Disorders.

Authors:  Theodoros Bermperidis; Simon Schafer; Fred H Gage; Terrence Sejnowski; Elizabeth B Torres
Journal:  Front Neurosci       Date:  2022-06-02       Impact factor: 5.152

2.  Motor Behavior is Relevant for Understanding Mechanism, Bolstering Prediction, And Improving Treatment: A Transdiagnostic Perspective.

Authors:  Sebastian Walther; Vijay A Mittal
Journal:  Schizophr Bull       Date:  2022-06-21       Impact factor: 7.348

3.  Extrapyramidal symptoms predict cognitive performance after first-episode psychosis.

Authors:  Maija Lindgren; Sebastian Therman; Anna Avellan; Tiina From; Jarmo Hietala; Minna Holm; Tuula Ilonen; Tuula Kieseppä; Heikki Laurikainen; Raimo K R Salokangas; Jaana Suvisaari
Journal:  Schizophrenia (Heidelb)       Date:  2022-08-04

4.  Measuring catatonia motor behavior with objective instrumentation.

Authors:  Sofie von Känel; Niluja Nadesalingam; Danai Alexaki; Daniel Baumann Gama; Alexandra Kyrou; Stéphanie Lefebvre; Sebastian Walther
Journal:  Front Psychiatry       Date:  2022-08-17       Impact factor: 5.435

5.  Different faces of catatonia and how to approach them.

Authors:  Dusan Hirjak; Fabio Sambataro; Georg Northoff; Robert Christian Wolf
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-01-17       Impact factor: 5.760

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.